MRD-positive AML Clinical Study
ConditionAML, Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14+
SponsorInstitute of Hematology & Blood Diseases Hospital, China
About this trial
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Eligibility criteria
Qualifiers
AML (non-M3) compliant with WHO (2016) standards;
In morphological complete remission.
Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive.
Age over 14 years old, male or female. Informed consent must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, informed consent must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family.
Disqualifiers
Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks
The diagnosis is APL
Those who were not considered suitable for inclusion by the researchers.
Trial design
Treatments tested in this trial
- Ivosidenib
- Gilteritinib
- Venetoclax
- Avapritinib
- Daunorubicin
- Cytarabine
- Idarubicin
- MTZ
- HHT
- Azacitidine
Treatment groups
120 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov